Apolipoprotein E polymorphism affects the response to pravastatin on plasma apolipoproteins in diabetic patients

Jun Watanabe, Kunihisa Kobayashi, Fumio Umeda, Teruaki Yamauchi, Kazuo Mimura, Naoki Nakashima, Mitsunori Masakado, Shinsuke Hiramatsu, Hajime Nawata

研究成果: Contribution to journalArticle査読

17 被引用数 (Scopus)

抄録

In the present study, we examined the levels of plasma lipids and apolipoproteins in patients with non-insulin dependent diabetes mellitus (NIDDM) with hypercholesterolemia in different apolipoprotein E (apo E) phenotypes. We also examined the influences of apo E polymorphism on the response to pravastatin. The patients were divided into three groups, E4/E3, E3/E3, and E3/E2. There were no differences in the baseline levels of plasma lipids and apolipoproteins, except that the level of triglycerides in E3/E2 heterozygotes was significantly higher than E3/E3 homozygotes. Three months of pravastatin administration significantly reduced plasma levels of total cholesterol and low-density lipoprotein cholesterol in each group to the same degree. We observed a significant reduction of apo B both in the E4/E3 and E3/E3 groups and apo E in the E3/E3 group. Such reduction was not observed in the E3/E2 group. We conclude that pravastatin is a potent drug to correct lipid abnormalities, particularly in NIDDM patients with apo E4/E3 and E3/E3. In the E3/E2 group, its effectiveness may be diminished.

本文言語英語
ページ(範囲)21-27
ページ数7
ジャーナルDiabetes Research and Clinical Practice
20
1
DOI
出版ステータス出版済み - 4 1993

All Science Journal Classification (ASJC) codes

  • 内科学
  • 内分泌学、糖尿病および代謝内科学
  • 内分泌学

フィンガープリント

「Apolipoprotein E polymorphism affects the response to pravastatin on plasma apolipoproteins in diabetic patients」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル